- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Kilitch Drugs (India) Ltd. board met to approve its Q1 FY26 consolidated financial results. Sales jumped to Rs 43.14 Cr, up from Rs 33.45 Cr in Q1 FY25. Profit after tax saw a significant surge to Rs 2.26 Cr, compared to Rs 0.11 Cr in the prior year.
The board also cleared a Rights Issue to raise Rs 49.93 Cr, offering 2 new shares for every 23 held at Rs 357 each. Key leadership updates include the re-appointment of Mr. Mukund Mehta as Managing Director for another five years and the continuation of Mr. Vasudev Krishna Murti as an Independent Director, both subject to shareholder approval at the upcoming 33rd Annual General Meeting.